Novel Drug for NCFBE Receives Breakthrough Therapy Designation
As reported in BioSpace; the US Food and Drug Administration (FDA) has granted breakthrough therapy designation, an expedited drug review, to brensocatib, a novel drug to treat non-cystic fibrosis bronchiectasis…